Last €228.39 EUR
Change Today +23.78 / 11.62%
Volume 1.6K
As of 10:51 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

pharmacyclics inc (PY2) Snapshot

Open
€231.00
Previous Close
€204.60
Day High
€245.00
Day Low
€215.47
52 Week High
03/5/15 - €245.00
52 Week Low
04/14/14 - €61.00
Market Cap
17.4B
Average Volume 10 Days
251.4
EPS TTM
--
Shares Outstanding
76.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMACYCLICS INC (PY2)

pharmacyclics inc (PY2) Related Businessweek News

View More BusinessWeek News

pharmacyclics inc (PY2) Details

Pharmacyclics, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for the treatment of cancer and immune-mediated diseases in the United States. The company markets IMBRUVICA, a first-in-class, oral, once-daily, single-agent therapy used for the treatment of patients with: chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17; mantle cell lymphoma who have received at least one prior therapy; and all lines of waldenström's macroglobulinemia (WM). Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under phase I, II, III clinical trials for the treatment of CCL, small lymphocytic lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, multiple myeloma, WM, marginal zone lymphoma, graft versus host disease, acute lymphoblastic leukemia, acute myeloid leukemia, and solid tumors and others. The company’s product candidates also comprise BTK Inhibitor Program that is in pre-clinical testing, phase I for the treatment of autoimmune; Abexinostat HDAC Inhibitor, which is in phase I and II clinical trials for treating relapsed/refractory lymphomas and solid tumors; and Factor VIIa Inhibitor, which is in phase II complete/program under review for the treatment of cancer. Pharmacyclics, Inc. has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize IMBRUVICA and certain compounds for oncology and other indications. The company was founded in 1991 and is headquartered in Sunnyvale, California.

607 Employees
Last Reported Date: 02/18/15
Founded in 1991

pharmacyclics inc (PY2) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: --
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $541.1K
Chief Operating Officer
Total Annual Compensation: $849.2K
Chief of Quality & Technical Operations
Total Annual Compensation: $704.3K
Compensation as of Fiscal Year 2013.

pharmacyclics inc (PY2) Key Developments

AbbVie Inc., Pharmacyclics Inc. - M&A Call

To consider definitive agreement under which AbbVie will acquire Pharmacyclics, and its Imbruvica® (ibrutinib), a highly effective treatment for hematologic malignancies

Pharmacyclics Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

Pharmacyclics Inc. announced unaudited consolidated financial results for the fourth quarter and year ended December 31, 2014. The company reported revenue of $290 million, up from $124 million in the year ago quarter, primarily due to a $172 million increase in Imbruvica net product revenue year over year. Non-GAAP earnings were $0.96, up from $0.30 per share last year. GAAP net income for the quarter ended December 31, 2014 was $63 million, or $0.81 per diluted share, compared to GAAP net income of $64 million or $0.82 per diluted share for the quarter ended December 31, 2013. Income from operations was $92.991 million against $85.431 million a year ago. Income before income taxes was $93.052 million against $85.439 million a year ago. Non-GAAP net income was $75.197 million or $0.96 per diluted share against $23.642 million or $0.30 per diluted share a year ago. For the year, the company reported total revenue of $729.729 million against $260.169 million a year ago. Income from operations was $122.381 million against $97.924 million a year ago. Income before income taxes was $122.447 million against $98.136 million a year ago. Net income was $86.124 million or $1.10 per diluted share against $67.010 million or $0.87 per diluted share a year ago. Non-GAAP net income was $140.385 million or $1.80 per diluted share against $1.083 million or $0.01 per basic and diluted share a year ago. Total revenue was increased primarily due to $479 million increase in IMBRUVICA net product revenue, as the year ended December 31, 2014 was first full year of IMBRUVICA product sales.

Pharmacyclics Inc. to Report Q4, 2014 Results on Feb 18, 2015

Pharmacyclics Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Feb 18, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PY2:GR €228.39 EUR +23.78

PY2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biogen Idec Inc $423.50 USD +9.37
Celgene Corp $120.75 USD +1.18
Genmab A/S kr546.50 DKK +25.50
Gilead Sciences Inc $103.67 USD +0.61
GlaxoSmithKline PLC 1,570 GBp +3.50
View Industry Companies
 

Industry Analysis

PY2

Industry Average

Valuation PY2 Industry Range
Price/Earnings 100.0x
Price/Sales 22.5x
Price/Book 19.9x
Price/Cash Flow 190.2x
TEV/Sales 21.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMACYCLICS INC, please visit www.pharmacyclics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.